Intrinsic value of Rydex Biotechnology Fund Class Investor (RYOIX)

Live fair value data for Rydex Biotechnology Fund Class Investor (RYOIX) is currently unavailable. Please check again shortly.

Fallback estimate (fair value API unavailable)

Intrinsic Value (Fair Value): Unlock fair value

Upside: +54.0%

Margin of Safety: +35.1%

Current Price: $331.00

Valuation: Undervalued

Confidence: 9.5/10

Visual Bar

Market Price $331.00Intrinsic Value Locked

Undervalued ✅Fair Value ⚖️Overvalued ❌

This intrinsic value is calculated using 5 different models based on projected revenue growth, profit margins, and a standard discount rate.

Is Rydex Biotechnology Fund Class Investor (RYOIX) undervalued or overvalued?

Based on the current model output, Rydex Biotechnology Fund Class Investor appears to be undervalued with a upside of 54.00%.

Fair value vs market price — Rydex Biotechnology Fund Class Investor (RYOIX)

Unlock premium access to view the live fair value comparison against current market price for RYOIX.

Unlock Fair Value

Frequently Asked Questions - RYOIX

How is RYOIX intrinsic value estimated?

We combine revenue growth, discount rate, and terminal growth assumptions to estimate a fair value range for RYOIX.

Is RYOIX undervalued or overvalued right now?

RYOIX is currently shown as undervalued based on the difference between market price and intrinsic value.

How should I use the confidence score?

The confidence score (0 to 10) indicates model certainty from available inputs. Higher values suggest stronger model consistency, not a guarantee of returns.

Related companies — intrinsic value

Peers for RYOIX: open their intrinsic value pages.

Explore Other Stocks

AAPL TSLA NVDA MSFT